Could you help your patients step into FREEDOM?
Introducing the FREEDOM-3 clinical trial
For your patients with diffuse cutaneous systemic sclerosis (dcSSc)
participant in the FREEDOM-3 trial.
The FREEDOM-3 clinical trial
This phase 1/2a trial will evaluate the safety, tolerability, and efficacy of an allogeneic hematopoietic stem cell transplant with an investigational cell therapy called FCR001 in people with rapidly progressing dcSSc and who are at risk for organ failure.
What is the purpose of this trial?
The FREEDOM-3 trial will help us assess the safety and efficacy of an investigational cell therapy called FCR001.
Who can participate?
We are looking for people with rapidly progressing dcSSc and who are at risk for organ failure.
How long is this trial?
All recipients will have regular study visits for about five years.
Take the next step for your patients
Thank you for taking the time to learn more about the FREEDOM-3 clinical trial.
in the FREEDOM-3 trial.